Steve Schonfeld’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$430K Buy
+90,008
New +$434K ﹤0.01% 2038
2022
Q4
– Sell
-31,900
Closed -$61K – 2540
2022
Q3
$61K Buy
+31,900
New +$75.1K ﹤0.01% 2614
2022
Q1
– Sell
-12,500
Closed -$49K – 2551
2021
Q4
$49K Sell
12,500
-133,300
-91% -$518K ﹤0.01% 1949
2021
Q3
$626K Buy
+145,800
New +$486K 0.01% 1166
2021
Q2
– Sell
-12,719
Closed -$42K – 1896
2021
Q1
$42K Buy
+12,719
New +$49.1K ﹤0.01% 1726
2017
Q4
– Sell
-125,000
Closed -$775K – 728
2017
Q3
$775K Buy
+125,000
New +$535K 0.07% 310

Other funds holding ABUS

Steve Schonfeld's ABUS Position: Q3 2026 in Review

Steve Schonfeld opened a new position in Arbutus Biopharma (ABUS) in Q3 2026: 90,008 shares worth $430K. The stake represents ﹤0.01% of the portfolio and ranks #2038 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in ABUS as recently as Q3 2022.

Steve Schonfeld first reported a position in ABUS in Q3 2017 and has held it in 6 quarters since. The position peaked at $775K in Q3 2017. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Steve Schonfeld held 90,008 shares of Arbutus Biopharma worth $430K as of Q3 2026.
  • Arbutus Biopharma was a new Steve Schonfeld position in Q3 2026.
  • Arbutus Biopharma made up ﹤0.01% of Steve Schonfeld's portfolio in Q3 2026, its #2038 holding.
  • Steve Schonfeld first reported a position in Arbutus Biopharma in Q3 2017 and has held it in 6 quarters since.
  • Steve Schonfeld's Arbutus Biopharma position peaked at $775K in Q3 2017.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.